Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the FDA means a product can stay on the market even after a health emergency ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...

Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...

Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...

A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...

Markets were also boosted by the prospect of a quieter geopolitical environment, as the US attempts to smooth the wrinkles in ...

Brinker, the owner of Chili's, has seen shares soar 20% so far in 2025. The earnings report on Tuesday could take them a leg up or down. The additional step, which could cost millions of dollars, goes ...